<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02499497</url>
  </required_header>
  <id_info>
    <org_study_id>15-120</org_study_id>
    <nct_id>NCT02499497</nct_id>
  </id_info>
  <brief_title>A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer</brief_title>
  <official_title>A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is studying the use of a targeted therapy called LY SARM, which is an&#xD;
      investigational drug from a new class of molecules called Selective Androgen Receptor&#xD;
      Modulators (SARMs) as a possible improvement in quality of life for participants who have&#xD;
      undergone radical prostatectomy. Androgens are a group of hormones that play a role in male&#xD;
      traits and reproductive activity.&#xD;
&#xD;
      The names of the study interventions involved in this study are:&#xD;
&#xD;
      - LY2452473&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Phase II clinical trial. Phase II clinical trials test the safety&#xD;
      and effectiveness of an investigational intervention to learn whether the intervention works&#xD;
      in treating a specific disease. &quot;Investigational&quot; means that the intervention is being&#xD;
      studied.&#xD;
&#xD;
      The FDA (the U.S. Food and Drug Administration) has not approved LY SARM/LY2452473 as a&#xD;
      treatment for any disease.&#xD;
&#xD;
      In this research study, the investigators are studying a new investigational drug called LY&#xD;
      SARM (LY2452473). Concerns about the potential adverse effects of testosterone on the&#xD;
      prostate have led to the development of molecules called SARMs (Selective Androgen Receptor&#xD;
      Modulators). This investigational drug may improve sexual function, quality of life, muscle&#xD;
      and bone mass in men with prostate cancer. This molecule was chosen because there is some&#xD;
      evidence that shows it may help to improve sexual function and aid in the improvement of&#xD;
      muscle mass while not having any influence on the prostate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 29, 2016</start_date>
  <completion_date type="Actual">October 31, 2020</completion_date>
  <primary_completion_date type="Actual">October 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Sexual Activity Score of Psychosexual Daily Questionnaire (PDQ-4)</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>The primary outcome is change in sexual activity score, assessed by the Psychosexual Daily Questionnaire (PDQ). The questionnaire covered 3 different domains: 1) sexual desire, enjoyment, and performance; 2) sexual activity score; and 3) mood. Sexual activity was assessed using a checklist format (12-item) and the score range of 0 to 12 with higher scores representing better sexual activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in All Domains of International Index of Erectile Function (IIEF)</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sexual Activity, Interest, and Desire Scale (SAID)</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>The Sexual Activity, Interest, and Desire Scale (SAID) is an 8-item questionnaire that evaluates 3 response domains, including sexual thinking, sexual arousal, and sexual activity. The score was linearly transformed to a 0 to 100 scale for each item. The average score ranges 0-100. The higher the score, the better the sexual function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Derogatis Index of Sexual Function Male II (DISF-M-II)</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Derogatis Index of Sexual Function Male II (DISF-M-II) is a 25-item questionnaire that provides an estimate of perceived quality of sexual activities in 5 response domains: sexual desire/drive (range 0-33), sexual arousal (range 0-33), sexual activity (range 0-35), orgasm (range 0-26), and sexual satisfaction/partner relationship (range 0-25). The total possible score (sum of 5 domains) range of 0 to 152 with higher scores representing better function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Three Domains of Men's Sexual Health Questionnaire (MSHQ)</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Men's Sexual Health Questionnaire (MSHQ), a 25-item questionnaire, assesses sexual function and satisfaction. It consists 5 domains: Erection (3 items, ranging from 0 to 15 (best)), Ejaculation (7 items, ranging from 1 to 35 (best)), Satisfaction (6 items, ranging from 6 to 30 (best)), Sexual desire (4 items, ranging 4-20 (best)), and Sexual activity (3 items, ranging 3-15 (best)). Erection, Ejaculation and Satisfaction domains were measured and the higher score representing better sexual function and satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Two Domains of Expanded Prostate Cancer Index Composite (EPIC)</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Expanded Prostate Cancer Index Composite (EPIC) is a 50-item, comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Of its four domains, the sexual domain (range 0-100) and hormonal domain (range 0-100) were utilized. The response for each item is standardized to a 0 to 100 scale. Higher score yields better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>The FACIT Fatigue Scale is a 13-item questionnaire that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point scale (4 = not at all fatigued to 0 = very much fatigued). Score ranges 0-52. The higher the score, the better the quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hypogonadism Energy Diary (HED)</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Hypogonadism Energy Diary (HED) is a 4-item questionnaire that intended to assess real-time energy levels. Score ranges 0 to100 with higher scores representing higher energy. each question uses an 11-point numerical rating scale (0-10) with 10 corresponding to full of energy or extreme tiredness. HED score was the average of the scores for these 4 items. Scores were linearly transformed to a 0 to 100 scale. Higher scores representing higher energy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International Prostate Symptom Score (IPSS)</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>International Prostate Symptom Score (IPSS) is a 8-item, extensively validated and widely used self-reported measure of lower urinary tract symptoms questionnaire. It includes Urinary Symptoms (item1-7, range 0-35) and Quality of Life Due to Urinary Symptoms (item 8, range 0-6). The higher the score, the severer of the urinary symptoms and worse quality of life due to symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Positive and Negative Affect Scale (PANAS)</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire that consists of two 10-item scales to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (very slightly or not at all) to 5 (extremely). Score ranges 10-50 for both positive and negative affect. The higher scores represent higher levels of positive/negative affect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Using DXA</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Whole body, appendicular, and trunk lean mass were measured using dual energy X- ray absorptiometry (DXA), calibrated using a soft tissue phantom before each scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Maximal Voluntary Muscle Strength</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>The maximal voluntary muscle strength was measured in the leg press exercise using the 1-repetition method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gait Speed in 6-minute Walk</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Tests of Physical Function and Task-Specific Performance measured by gait speed in 6-min walk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of 50 Meters Walk Tests- Unloaded /Loaded</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Tests of Physical Function and Task-Specific Performance measured by 50-meter timed walk + 20% load carry. Physical Function was evaluated using test of 50-meter loaded walking speed. One test consisted of walking 50 meters as rapidly as possible without running (unloaded) while the second test required participants to carry a load equivalent to 20% of their baseline body weight evenly distributed in two canvas tote bags(loaded). Time was measured electronically with a digital clock. Speed in meters per second is calculated by the following: 50/time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Power of Stair Climbing Tests- Unloaded/Loaded</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Tests of Physical Function and Task-Specific Performance measured by Stair-climbing power +/- 20% load carry. Physical Function was evaluated using two tests of stair climb power using an indoor 12-step staircase. One test consisted of ascending the 12-steps as rapidly as possible without running (unloaded stair climb) while the second test required participants to carry a load equivalent to 20% of their baseline body weight evenly distributed in two canvas tote bags (loaded stair climb). Time to ascend the stairs was measured electronically with a digital clock and switch mats placed at the base of the steps and on the 12th step. Power in watts is calculated by the following: [body weight (kilograms) * distance (meters)/ (time/60)] /6.12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Total Testosterone Level</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Serum total testosterone levels during screening was measured in the Quest Diagnostics Laboratory, Chantilly, VA, using liquid chromatography tandem mass spectrometry (LC-MS/MS) method certified by the Hormone Standardization Program for Testosterone (HoST) of the Centers for Disease Control and Prevention, Atlanta, Georgia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Free Testosterone Level</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Free testosterone level for screening was measured using an equilibrium dialysis method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Sex Hormone-binding Globulin (SHBG) Level</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Serum SHBG level was measured using two-site directed immuno-chemiluminescence assays with sensitivity 2.5 nmol/L, and coefficients of variation less than 10% in low, medium and high range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Luteinizing Hormone (LH) Level</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Serum LH level was measured using two-site directed immuno-chemiluminescence assays with sensitivity 0.1 U/L, and coefficients of variation less than 10% in low, medium and high range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estradiol Levels</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Estradiol level was measured by LC-MS/MS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of White Blood Cell</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>White Blood Cell was measured for safety monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Red Blood Cell</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Red Blood Cell was measured for safety monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hematocrit</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Hematocrit was measured for safety monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Hemoglobin was measured for safety monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Mean Corpuscular Volume (MCV)</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Mean corpuscular volume was measured for safety monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Red Blood Cell Distribution Width (RDW)</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Red blood cell distribution width (RDW) was measured for safety monitoring. RDW was calculated with: standard deviation of the mean cell size divided by the mean corpuscular volume of the red cells multiplied by 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Platelet Count</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Platelet count was measured for safety monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Aspartate Aminotransferase (AST)</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Aspartate aminotransferase was measured for safety monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Alanine Aminotransferase (ALT)</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Alanine aminotransferase was measured for safety monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Total Bilirubin</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Total Bilirubin was measured for safety monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Alkaline Phosphatase</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Serum alkaline phosphatase was measured for safety monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Lipid Panel</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Plasma lipids were measured for safety monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Glucose Levels</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Glucose will be measured in a fasting serum sample at Quest Lab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin</measure>
    <time_frame>12 weeks from baseline</time_frame>
    <description>Insulin will be measured using an immunoassay at Quest lab.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2452473 Dose 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2452473 Dose 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1 or LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2452473 Dose 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2452473</intervention_name>
    <description>LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
    <arm_group_label>LY2452473 Dose 1</arm_group_label>
    <arm_group_label>LY2452473 Dose 2</arm_group_label>
    <arm_group_label>LY2452473 Dose 3</arm_group_label>
    <other_name>Selective Androgen Receptor Modulator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The participants will receive pills containing no active drug.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age 19 years of age or older&#xD;
&#xD;
          -  History of prostate cancer&#xD;
&#xD;
               -  Stage pathological tumor-2 (pT2) N0, M0 lesions (If American Joint Committee on&#xD;
                  Cancer (AJCC) staging is not available in medical records, the investigators will&#xD;
                  infer the staging based on extensive review of the pathology report)&#xD;
&#xD;
               -  Combined Gleason score &lt; 7 (3+4)&#xD;
&#xD;
               -  Radical prostatectomy two or more years ago&#xD;
&#xD;
               -  Preoperative prostate-specific antigen (PSA)&lt;10 ng/ml (if pre-operative PSA is&#xD;
                  not available in medical records, low-risk subjects with a Gleason score of&#xD;
                  6(3+3) and who are at least 5 years out of surgery will be considered for&#xD;
                  enrollment)&#xD;
&#xD;
               -  PSA &lt;0.1 ng/mL using an assay that has a functional sensitivity of 0.1 ng/mL for&#xD;
                  at least two years after radical prostatectomy&#xD;
&#xD;
          -  Serum testosterone, measured by Liquid chromatography-tandem mass spectrometry&#xD;
             (LC-MS/MS), &lt;300 mg/dL and/or free testosterone by equilibrium dialysis &lt;60 pg/mL.&#xD;
&#xD;
             * Derogatis Index of Sexual Function Male II (DISF-M-II) score â‰¤20, fatigue (FACIT-F&#xD;
             score &lt;30), or physical dysfunction (self-reported difficulty in walking a 1/4 mile or&#xD;
             climbing two flights of stairs, short physical performance battery score 4 to 9).&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
               -  Agree to use adequate contraception prior to receiving the study drug, for the&#xD;
                  duration of study participation, and 4 months after completion of LY SARM&#xD;
                  administration.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  History of radiation monotherapy&#xD;
&#xD;
          -  History of androgen deprivation therapy&#xD;
&#xD;
          -  Use of testosterone, dehydroepiandrosterone (DHEA), estrogens, gonadotropin-releasing&#xD;
             hormone (GnRH) analogs, antiandrogens, spironolactone, ketoconazole, recombinant human&#xD;
             growth hormone (rhGH), or megestrol acetate within the past 6 months&#xD;
&#xD;
          -  Use of prednisone 20 mg daily or equivalent doses of other glucocorticoids for more&#xD;
             than two weeks within the past 6 months&#xD;
&#xD;
          -  Use of Clarithromycin, telithromycin, chloramphenicol, itraconazole, nefazodone,&#xD;
             cobicistat within the past 6 months&#xD;
&#xD;
          -  Use of penile implants, vacuum pump devices, intra-cavernosal injections&#xD;
&#xD;
          -  Hematocrit &gt;50%&#xD;
&#xD;
          -  Serum creatinine &gt;2.5 mg/dL&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) greater than 3x upper limit of normal (ULN)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) greater than 3x ULN&#xD;
&#xD;
          -  Hemoglobin A1c &gt;7.5%&#xD;
&#xD;
          -  Body mass index (BMI) &gt;40 kg/m2&#xD;
&#xD;
          -  Diabetes requiring insulin therapy&#xD;
&#xD;
          -  Severe untreated sleep apnea (treatment is defined as therapy with continuous positive&#xD;
             airway pressure (CPAP), BiPAP, adaptive servo-ventilation (ASV), or other positive air&#xD;
             pressure device)&#xD;
&#xD;
          -  Uncontrolled heart failure (NYHA class 3 or 4)&#xD;
&#xD;
          -  History of HIV&#xD;
&#xD;
          -  Myocardial infarction within the last 3 months&#xD;
&#xD;
          -  Acute coronary syndrome within the last 3 months&#xD;
&#xD;
          -  Revascularization surgery within the last 3 months&#xD;
&#xD;
          -  Stroke within the last 3 months&#xD;
&#xD;
          -  Diagnosed schizophrenia or bipolar disorder or untreated depression&#xD;
&#xD;
          -  Not appropriate for study based on physician discretion&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shalender Bhasin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center (Referring site only)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <results_first_submitted>August 23, 2021</results_first_submitted>
  <results_first_submitted_qc>September 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 28, 2021</results_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Shalender Bhasin, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02499497/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
        </group>
        <group group_id="P2">
          <title>LY2452473 Dose 1</title>
          <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
N-[(2S)-7-cyano-1,2,3,4-tetrahydro-4-(2-pyridinylmethyl)cyclopent[b]indol-2-yl]-,1-methylester (LY2452473): LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
        </group>
        <group group_id="P3">
          <title>LY2452473 Dose 2</title>
          <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
        </group>
        <group group_id="P4">
          <title>LY2452473 Dose 3</title>
          <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
        </group>
        <group group_id="B2">
          <title>LY2452473 Dose 1</title>
          <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
        </group>
        <group group_id="B3">
          <title>LY2452473 Dose 2</title>
          <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
        </group>
        <group group_id="B4">
          <title>LY2452473 Dose 3</title>
          <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="14"/>
            <count group_id="B5" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="36"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="6.1"/>
                    <measurement group_id="B2" value="67.1" spread="7.87"/>
                    <measurement group_id="B3" value="67.4" spread="8.6"/>
                    <measurement group_id="B4" value="69.6" spread="7.1"/>
                    <measurement group_id="B5" value="67.5" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="36"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="36"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="36"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.9" spread="12.7"/>
                    <measurement group_id="B2" value="92.7" spread="10.7"/>
                    <measurement group_id="B3" value="89.7" spread="15.4"/>
                    <measurement group_id="B4" value="86.7" spread="12.5"/>
                    <measurement group_id="B5" value="88.5" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="36"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.9" spread="3.8"/>
                    <measurement group_id="B2" value="29.8" spread="3.89"/>
                    <measurement group_id="B3" value="29.3" spread="4.1"/>
                    <measurement group_id="B4" value="29.2" spread="5.1"/>
                    <measurement group_id="B5" value="29.0" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Short Physical Performance Battery (SPPB) score</title>
          <description>The short physical performance battery (SPPB) is a group of measures that combines the results of the gait speed, chair stand and balance tests. The scores range from 0 to 12. The higher the score, the better the performance.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="36"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="36"/>
                    <count group_id="B4" value="14"/>
                    <count group_id="B5" value="114"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.4" spread="1.15"/>
                    <measurement group_id="B2" value="11.1" spread="1.21"/>
                    <measurement group_id="B3" value="11.1" spread="1.42"/>
                    <measurement group_id="B4" value="11.1" spread="1.07"/>
                    <measurement group_id="B5" value="11.2" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Sexual Activity Score of Psychosexual Daily Questionnaire (PDQ-4)</title>
        <description>The primary outcome is change in sexual activity score, assessed by the Psychosexual Daily Questionnaire (PDQ). The questionnaire covered 3 different domains: 1) sexual desire, enjoyment, and performance; 2) sexual activity score; and 3) mood. Sexual activity was assessed using a checklist format (12-item) and the score range of 0 to 12 with higher scores representing better sexual activity.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sexual Activity Score of Psychosexual Daily Questionnaire (PDQ-4)</title>
          <description>The primary outcome is change in sexual activity score, assessed by the Psychosexual Daily Questionnaire (PDQ). The questionnaire covered 3 different domains: 1) sexual desire, enjoyment, and performance; 2) sexual activity score; and 3) mood. Sexual activity was assessed using a checklist format (12-item) and the score range of 0 to 12 with higher scores representing better sexual activity.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.19"/>
                    <measurement group_id="O2" value="0.45" spread="0.26"/>
                    <measurement group_id="O3" value="-0.02" spread="0.22"/>
                    <measurement group_id="O4" value="0.12" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in All Domains of International Index of Erectile Function (IIEF)</title>
        <description>IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in All Domains of International Index of Erectile Function (IIEF)</title>
          <description>IIEF is a validated, 15-item questionnaire that assesses 5 domains of sexual function: erectile function (range 1-30), orgasmic function (range 0-10), sexual desire (range 2-10), intercourse satisfaction (range 0-15), and overall sexual satisfaction (range 2-10). Each question was answered on a 6-point or 5-point scale from 0/1 to 5 (best) with a total possible score (sum of 5 domains) range of 5 to 75 with higher scores representing better function.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erectile Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.34" spread="1.02"/>
                    <measurement group_id="O2" value="0.92" spread="0.48"/>
                    <measurement group_id="O3" value="-0.50" spread="0.94"/>
                    <measurement group_id="O4" value="3.38" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intercourse satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.50"/>
                    <measurement group_id="O2" value="0.42" spread="0.25"/>
                    <measurement group_id="O3" value="-0.22" spread="0.39"/>
                    <measurement group_id="O4" value="0.92" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orgasmic function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.48"/>
                    <measurement group_id="O2" value="0.17" spread="0.32"/>
                    <measurement group_id="O3" value="-0.53" spread="0.57"/>
                    <measurement group_id="O4" value="0.75" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual desire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.22"/>
                    <measurement group_id="O2" value="0.46" spread="0.38"/>
                    <measurement group_id="O3" value="-0.19" spread="0.25"/>
                    <measurement group_id="O4" value="0.83" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.34"/>
                    <measurement group_id="O2" value="0.79" spread="0.32"/>
                    <measurement group_id="O3" value="0.31" spread="0.33"/>
                    <measurement group_id="O4" value="0.25" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite IIEF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.79" spread="1.96"/>
                    <measurement group_id="O2" value="2.73" spread="1.28"/>
                    <measurement group_id="O3" value="-1.22" spread="1.90"/>
                    <measurement group_id="O4" value="6.14" spread="5.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sexual Activity, Interest, and Desire Scale (SAID)</title>
        <description>The Sexual Activity, Interest, and Desire Scale (SAID) is an 8-item questionnaire that evaluates 3 response domains, including sexual thinking, sexual arousal, and sexual activity. The score was linearly transformed to a 0 to 100 scale for each item. The average score ranges 0-100. The higher the score, the better the sexual function.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sexual Activity, Interest, and Desire Scale (SAID)</title>
          <description>The Sexual Activity, Interest, and Desire Scale (SAID) is an 8-item questionnaire that evaluates 3 response domains, including sexual thinking, sexual arousal, and sexual activity. The score was linearly transformed to a 0 to 100 scale for each item. The average score ranges 0-100. The higher the score, the better the sexual function.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="2.36"/>
                    <measurement group_id="O2" value="4.25" spread="2.85"/>
                    <measurement group_id="O3" value="-3.00" spread="3.27"/>
                    <measurement group_id="O4" value="-1.50" spread="4.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Derogatis Index of Sexual Function Male II (DISF-M-II)</title>
        <description>Derogatis Index of Sexual Function Male II (DISF-M-II) is a 25-item questionnaire that provides an estimate of perceived quality of sexual activities in 5 response domains: sexual desire/drive (range 0-33), sexual arousal (range 0-33), sexual activity (range 0-35), orgasm (range 0-26), and sexual satisfaction/partner relationship (range 0-25). The total possible score (sum of 5 domains) range of 0 to 152 with higher scores representing better function.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Derogatis Index of Sexual Function Male II (DISF-M-II)</title>
          <description>Derogatis Index of Sexual Function Male II (DISF-M-II) is a 25-item questionnaire that provides an estimate of perceived quality of sexual activities in 5 response domains: sexual desire/drive (range 0-33), sexual arousal (range 0-33), sexual activity (range 0-35), orgasm (range 0-26), and sexual satisfaction/partner relationship (range 0-25). The total possible score (sum of 5 domains) range of 0 to 152 with higher scores representing better function.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sexual Desire</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.89"/>
                    <measurement group_id="O2" value="0.87" spread="1.63"/>
                    <measurement group_id="O3" value="-0.81" spread="0.97"/>
                    <measurement group_id="O4" value="1.08" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual Arousal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.62"/>
                    <measurement group_id="O2" value="0.83" spread="0.74"/>
                    <measurement group_id="O3" value="0.00" spread="0.74"/>
                    <measurement group_id="O4" value="0.67" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual Activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.65"/>
                    <measurement group_id="O2" value="0.96" spread="0.81"/>
                    <measurement group_id="O3" value="0.53" spread="0.67"/>
                    <measurement group_id="O4" value="0.67" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orgasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.82"/>
                    <measurement group_id="O2" value="0.57" spread="0.84"/>
                    <measurement group_id="O3" value="-0.31" spread="0.77"/>
                    <measurement group_id="O4" value="0.75" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.69"/>
                    <measurement group_id="O2" value="1.22" spread="1.18"/>
                    <measurement group_id="O3" value="0.22" spread="0.91"/>
                    <measurement group_id="O4" value="1.42" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Composite DISF-M-II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="2.70"/>
                    <measurement group_id="O2" value="4.43" spread="3.91"/>
                    <measurement group_id="O3" value="-0.36" spread="3.26"/>
                    <measurement group_id="O4" value="4.58" spread="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Three Domains of Men's Sexual Health Questionnaire (MSHQ)</title>
        <description>Men's Sexual Health Questionnaire (MSHQ), a 25-item questionnaire, assesses sexual function and satisfaction. It consists 5 domains: Erection (3 items, ranging from 0 to 15 (best)), Ejaculation (7 items, ranging from 1 to 35 (best)), Satisfaction (6 items, ranging from 6 to 30 (best)), Sexual desire (4 items, ranging 4-20 (best)), and Sexual activity (3 items, ranging 3-15 (best)). Erection, Ejaculation and Satisfaction domains were measured and the higher score representing better sexual function and satisfaction.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Three Domains of Men's Sexual Health Questionnaire (MSHQ)</title>
          <description>Men's Sexual Health Questionnaire (MSHQ), a 25-item questionnaire, assesses sexual function and satisfaction. It consists 5 domains: Erection (3 items, ranging from 0 to 15 (best)), Ejaculation (7 items, ranging from 1 to 35 (best)), Satisfaction (6 items, ranging from 6 to 30 (best)), Sexual desire (4 items, ranging 4-20 (best)), and Sexual activity (3 items, ranging 3-15 (best)). Erection, Ejaculation and Satisfaction domains were measured and the higher score representing better sexual function and satisfaction.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.36"/>
                    <measurement group_id="O2" value="0.80" spread="0.52"/>
                    <measurement group_id="O3" value="-0.65" spread="0.48"/>
                    <measurement group_id="O4" value="1.30" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ejaculation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="1.15"/>
                    <measurement group_id="O2" value="2.38" spread="1.72"/>
                    <measurement group_id="O3" value="-1.46" spread="1.16"/>
                    <measurement group_id="O4" value="-1.55" spread="3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.58"/>
                    <measurement group_id="O2" value="0.98" spread="0.85"/>
                    <measurement group_id="O3" value="-0.40" spread="0.84"/>
                    <measurement group_id="O4" value="1.27" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Two Domains of Expanded Prostate Cancer Index Composite (EPIC)</title>
        <description>Expanded Prostate Cancer Index Composite (EPIC) is a 50-item, comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Of its four domains, the sexual domain (range 0-100) and hormonal domain (range 0-100) were utilized. The response for each item is standardized to a 0 to 100 scale. Higher score yields better quality of life.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Two Domains of Expanded Prostate Cancer Index Composite (EPIC)</title>
          <description>Expanded Prostate Cancer Index Composite (EPIC) is a 50-item, comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. Of its four domains, the sexual domain (range 0-100) and hormonal domain (range 0-100) were utilized. The response for each item is standardized to a 0 to 100 scale. Higher score yields better quality of life.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sexual function</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="34"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="2.14"/>
                    <measurement group_id="O2" value="3.68" spread="3.04"/>
                    <measurement group_id="O3" value="0.08" spread="2.52"/>
                    <measurement group_id="O4" value="5.77" spread="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hormonal function</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="1.06"/>
                    <measurement group_id="O2" value="0.44" spread="2.04"/>
                    <measurement group_id="O3" value="0.52" spread="1.22"/>
                    <measurement group_id="O4" value="6.25" spread="5.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale</title>
        <description>The FACIT Fatigue Scale is a 13-item questionnaire that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point scale (4 = not at all fatigued to 0 = very much fatigued). Score ranges 0-52. The higher the score, the better the quality of life.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale</title>
          <description>The FACIT Fatigue Scale is a 13-item questionnaire that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four-point scale (4 = not at all fatigued to 0 = very much fatigued). Score ranges 0-52. The higher the score, the better the quality of life.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="1.30"/>
                    <measurement group_id="O2" value="2.29" spread="1.36"/>
                    <measurement group_id="O3" value="-0.36" spread="1.28"/>
                    <measurement group_id="O4" value="0.26" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hypogonadism Energy Diary (HED)</title>
        <description>Hypogonadism Energy Diary (HED) is a 4-item questionnaire that intended to assess real-time energy levels. Score ranges 0 to100 with higher scores representing higher energy. each question uses an 11-point numerical rating scale (0-10) with 10 corresponding to full of energy or extreme tiredness. HED score was the average of the scores for these 4 items. Scores were linearly transformed to a 0 to 100 scale. Higher scores representing higher energy.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hypogonadism Energy Diary (HED)</title>
          <description>Hypogonadism Energy Diary (HED) is a 4-item questionnaire that intended to assess real-time energy levels. Score ranges 0 to100 with higher scores representing higher energy. each question uses an 11-point numerical rating scale (0-10) with 10 corresponding to full of energy or extreme tiredness. HED score was the average of the scores for these 4 items. Scores were linearly transformed to a 0 to 100 scale. Higher scores representing higher energy.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="2.78"/>
                    <measurement group_id="O2" value="2.71" spread="2.82"/>
                    <measurement group_id="O3" value="2.64" spread="3.42"/>
                    <measurement group_id="O4" value="1.73" spread="5.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in International Prostate Symptom Score (IPSS)</title>
        <description>International Prostate Symptom Score (IPSS) is a 8-item, extensively validated and widely used self-reported measure of lower urinary tract symptoms questionnaire. It includes Urinary Symptoms (item1-7, range 0-35) and Quality of Life Due to Urinary Symptoms (item 8, range 0-6). The higher the score, the severer of the urinary symptoms and worse quality of life due to symptoms.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in International Prostate Symptom Score (IPSS)</title>
          <description>International Prostate Symptom Score (IPSS) is a 8-item, extensively validated and widely used self-reported measure of lower urinary tract symptoms questionnaire. It includes Urinary Symptoms (item1-7, range 0-35) and Quality of Life Due to Urinary Symptoms (item 8, range 0-6). The higher the score, the severer of the urinary symptoms and worse quality of life due to symptoms.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urinary Symptoms</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.59"/>
                    <measurement group_id="O2" value="-2.08" spread="0.65"/>
                    <measurement group_id="O3" value="0.06" spread="0.48"/>
                    <measurement group_id="O4" value="0.00" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quality of Life Due to Urinary Symptoms</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="35"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.13"/>
                    <measurement group_id="O2" value="-0.17" spread="0.17"/>
                    <measurement group_id="O3" value="-0.03" spread="0.18"/>
                    <measurement group_id="O4" value="-0.15" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Positive and Negative Affect Scale (PANAS)</title>
        <description>The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire that consists of two 10-item scales to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (very slightly or not at all) to 5 (extremely). Score ranges 10-50 for both positive and negative affect. The higher scores represent higher levels of positive/negative affect.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Positive and Negative Affect Scale (PANAS)</title>
          <description>The Positive and Negative Affect Schedule (PANAS) is a self-report questionnaire that consists of two 10-item scales to measure both positive and negative affect. Each item is rated on a 5-point scale of 1 (very slightly or not at all) to 5 (extremely). Score ranges 10-50 for both positive and negative affect. The higher scores represent higher levels of positive/negative affect.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive Affect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.89"/>
                    <measurement group_id="O2" value="0.75" spread="1.84"/>
                    <measurement group_id="O3" value="1.42" spread="1.03"/>
                    <measurement group_id="O4" value="-0.77" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.70" spread="0.72"/>
                    <measurement group_id="O2" value="-1.38" spread="0.58"/>
                    <measurement group_id="O3" value="0.42" spread="0.58"/>
                    <measurement group_id="O4" value="-2.77" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Mass Using DXA</title>
        <description>Whole body, appendicular, and trunk lean mass were measured using dual energy X- ray absorptiometry (DXA), calibrated using a soft tissue phantom before each scan.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Using DXA</title>
          <description>Whole body, appendicular, and trunk lean mass were measured using dual energy X- ray absorptiometry (DXA), calibrated using a soft tissue phantom before each scan.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Appendicular Fat Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.11"/>
                    <measurement group_id="O2" value="-0.19" spread="0.10"/>
                    <measurement group_id="O3" value="-0.36" spread="0.11"/>
                    <measurement group_id="O4" value="-0.13" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Fat Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.14"/>
                    <measurement group_id="O2" value="-0.32" spread="0.18"/>
                    <measurement group_id="O3" value="-0.38" spread="0.16"/>
                    <measurement group_id="O4" value="-0.72" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Fat Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.22"/>
                    <measurement group_id="O2" value="-0.52" spread="0.24"/>
                    <measurement group_id="O3" value="-0.75" spread="0.22"/>
                    <measurement group_id="O4" value="-0.86" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appendicular Lean Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.10"/>
                    <measurement group_id="O2" value="0.15" spread="0.13"/>
                    <measurement group_id="O3" value="0.80" spread="0.13"/>
                    <measurement group_id="O4" value="1.05" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trunk Lean Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.12"/>
                    <measurement group_id="O2" value="0.20" spread="0.19"/>
                    <measurement group_id="O3" value="0.68" spread="0.19"/>
                    <measurement group_id="O4" value="0.88" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Lean Mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.16"/>
                    <measurement group_id="O2" value="0.33" spread="0.27"/>
                    <measurement group_id="O3" value="1.48" spread="0.28"/>
                    <measurement group_id="O4" value="1.92" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Maximal Voluntary Muscle Strength</title>
        <description>The maximal voluntary muscle strength was measured in the leg press exercise using the 1-repetition method</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Maximal Voluntary Muscle Strength</title>
          <description>The maximal voluntary muscle strength was measured in the leg press exercise using the 1-repetition method</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>N</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.6" spread="55.0"/>
                    <measurement group_id="O2" value="108.1" spread="56.8"/>
                    <measurement group_id="O3" value="48.1" spread="29.4"/>
                    <measurement group_id="O4" value="103.5" spread="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Gait Speed in 6-minute Walk</title>
        <description>Tests of Physical Function and Task-Specific Performance measured by gait speed in 6-min walk</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Gait Speed in 6-minute Walk</title>
          <description>Tests of Physical Function and Task-Specific Performance measured by gait speed in 6-min walk</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.02"/>
                    <measurement group_id="O2" value="0.07" spread="0.02"/>
                    <measurement group_id="O3" value="0.08" spread="0.02"/>
                    <measurement group_id="O4" value="0.05" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of 50 Meters Walk Tests- Unloaded /Loaded</title>
        <description>Tests of Physical Function and Task-Specific Performance measured by 50-meter timed walk + 20% load carry. Physical Function was evaluated using test of 50-meter loaded walking speed. One test consisted of walking 50 meters as rapidly as possible without running (unloaded) while the second test required participants to carry a load equivalent to 20% of their baseline body weight evenly distributed in two canvas tote bags(loaded). Time was measured electronically with a digital clock. Speed in meters per second is calculated by the following: 50/time.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of 50 Meters Walk Tests- Unloaded /Loaded</title>
          <description>Tests of Physical Function and Task-Specific Performance measured by 50-meter timed walk + 20% load carry. Physical Function was evaluated using test of 50-meter loaded walking speed. One test consisted of walking 50 meters as rapidly as possible without running (unloaded) while the second test required participants to carry a load equivalent to 20% of their baseline body weight evenly distributed in two canvas tote bags(loaded). Time was measured electronically with a digital clock. Speed in meters per second is calculated by the following: 50/time.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>m/sec</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unloaded</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.03"/>
                    <measurement group_id="O2" value="0.12" spread="0.04"/>
                    <measurement group_id="O3" value="0.03" spread="0.02"/>
                    <measurement group_id="O4" value="0.07" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loaded</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.03"/>
                    <measurement group_id="O2" value="0.13" spread="0.05"/>
                    <measurement group_id="O3" value="0.05" spread="0.04"/>
                    <measurement group_id="O4" value="0.09" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Power of Stair Climbing Tests- Unloaded/Loaded</title>
        <description>Tests of Physical Function and Task-Specific Performance measured by Stair-climbing power +/- 20% load carry. Physical Function was evaluated using two tests of stair climb power using an indoor 12-step staircase. One test consisted of ascending the 12-steps as rapidly as possible without running (unloaded stair climb) while the second test required participants to carry a load equivalent to 20% of their baseline body weight evenly distributed in two canvas tote bags (loaded stair climb). Time to ascend the stairs was measured electronically with a digital clock and switch mats placed at the base of the steps and on the 12th step. Power in watts is calculated by the following: [body weight (kilograms) * distance (meters)/ (time/60)] /6.12.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Power of Stair Climbing Tests- Unloaded/Loaded</title>
          <description>Tests of Physical Function and Task-Specific Performance measured by Stair-climbing power +/- 20% load carry. Physical Function was evaluated using two tests of stair climb power using an indoor 12-step staircase. One test consisted of ascending the 12-steps as rapidly as possible without running (unloaded stair climb) while the second test required participants to carry a load equivalent to 20% of their baseline body weight evenly distributed in two canvas tote bags (loaded stair climb). Time to ascend the stairs was measured electronically with a digital clock and switch mats placed at the base of the steps and on the 12th step. Power in watts is calculated by the following: [body weight (kilograms) * distance (meters)/ (time/60)] /6.12.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>watts</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unloaded</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="26.1"/>
                    <measurement group_id="O2" value="19.7" spread="19.6"/>
                    <measurement group_id="O3" value="1.8" spread="15.6"/>
                    <measurement group_id="O4" value="51.7" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loaded</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="24.89"/>
                    <measurement group_id="O2" value="-36.6" spread="24.9"/>
                    <measurement group_id="O3" value="-9.8" spread="21.5"/>
                    <measurement group_id="O4" value="59.4" spread="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Total Testosterone Level</title>
        <description>Serum total testosterone levels during screening was measured in the Quest Diagnostics Laboratory, Chantilly, VA, using liquid chromatography tandem mass spectrometry (LC-MS/MS) method certified by the Hormone Standardization Program for Testosterone (HoST) of the Centers for Disease Control and Prevention, Atlanta, Georgia.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Total Testosterone Level</title>
          <description>Serum total testosterone levels during screening was measured in the Quest Diagnostics Laboratory, Chantilly, VA, using liquid chromatography tandem mass spectrometry (LC-MS/MS) method certified by the Hormone Standardization Program for Testosterone (HoST) of the Centers for Disease Control and Prevention, Atlanta, Georgia.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="15.8"/>
                    <measurement group_id="O2" value="-83.5" spread="21.3"/>
                    <measurement group_id="O3" value="-172.3" spread="27.6"/>
                    <measurement group_id="O4" value="-185.2" spread="46.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Free Testosterone Level</title>
        <description>Free testosterone level for screening was measured using an equilibrium dialysis method.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Free Testosterone Level</title>
          <description>Free testosterone level for screening was measured using an equilibrium dialysis method.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.15"/>
                    <measurement group_id="O2" value="0.59" spread="0.18"/>
                    <measurement group_id="O3" value="1.43" spread="0.20"/>
                    <measurement group_id="O4" value="1.62" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Sex Hormone-binding Globulin (SHBG) Level</title>
        <description>Serum SHBG level was measured using two-site directed immuno-chemiluminescence assays with sensitivity 2.5 nmol/L, and coefficients of variation less than 10% in low, medium and high range</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Sex Hormone-binding Globulin (SHBG) Level</title>
          <description>Serum SHBG level was measured using two-site directed immuno-chemiluminescence assays with sensitivity 2.5 nmol/L, and coefficients of variation less than 10% in low, medium and high range</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.0"/>
                    <measurement group_id="O2" value="-9.6" spread="1.3"/>
                    <measurement group_id="O3" value="-21.7" spread="2.1"/>
                    <measurement group_id="O4" value="-24.2" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Luteinizing Hormone (LH) Level</title>
        <description>Serum LH level was measured using two-site directed immuno-chemiluminescence assays with sensitivity 0.1 U/L, and coefficients of variation less than 10% in low, medium and high range</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Luteinizing Hormone (LH) Level</title>
          <description>Serum LH level was measured using two-site directed immuno-chemiluminescence assays with sensitivity 0.1 U/L, and coefficients of variation less than 10% in low, medium and high range</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.27"/>
                    <measurement group_id="O2" value="0.11" spread="0.23"/>
                    <measurement group_id="O3" value="0.72" spread="1.27"/>
                    <measurement group_id="O4" value="-0.42" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estradiol Levels</title>
        <description>Estradiol level was measured by LC-MS/MS.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estradiol Levels</title>
          <description>Estradiol level was measured by LC-MS/MS.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.5"/>
                    <measurement group_id="O2" value="-1.1" spread="1.1"/>
                    <measurement group_id="O3" value="-5.5" spread="1.1"/>
                    <measurement group_id="O4" value="-7.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of White Blood Cell</title>
        <description>White Blood Cell was measured for safety monitoring.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of White Blood Cell</title>
          <description>White Blood Cell was measured for safety monitoring.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>K/uL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.15"/>
                    <measurement group_id="O2" value="0.30" spread="0.29"/>
                    <measurement group_id="O3" value="-0.21" spread="0.19"/>
                    <measurement group_id="O4" value="0.32" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Red Blood Cell</title>
        <description>Red Blood Cell was measured for safety monitoring.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Red Blood Cell</title>
          <description>Red Blood Cell was measured for safety monitoring.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>K/uL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.04"/>
                    <measurement group_id="O2" value="-0.05" spread="0.05"/>
                    <measurement group_id="O3" value="0.03" spread="0.03"/>
                    <measurement group_id="O4" value="0.06" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hematocrit</title>
        <description>Hematocrit was measured for safety monitoring.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hematocrit</title>
          <description>Hematocrit was measured for safety monitoring.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>percentage of volume of red cells</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="0.33"/>
                    <measurement group_id="O2" value="-0.30" spread="0.51"/>
                    <measurement group_id="O3" value="0.44" spread="0.25"/>
                    <measurement group_id="O4" value="0.11" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin</title>
        <description>Hemoglobin was measured for safety monitoring.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin</title>
          <description>Hemoglobin was measured for safety monitoring.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.11"/>
                    <measurement group_id="O2" value="-0.12" spread="0.16"/>
                    <measurement group_id="O3" value="0.09" spread="0.09"/>
                    <measurement group_id="O4" value="-0.01" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Mean Corpuscular Volume (MCV)</title>
        <description>Mean corpuscular volume was measured for safety monitoring.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Mean Corpuscular Volume (MCV)</title>
          <description>Mean corpuscular volume was measured for safety monitoring.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>fL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.30"/>
                    <measurement group_id="O2" value="0.44" spread="0.48"/>
                    <measurement group_id="O3" value="0.37" spread="0.31"/>
                    <measurement group_id="O4" value="-1.08" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Red Blood Cell Distribution Width (RDW)</title>
        <description>Red blood cell distribution width (RDW) was measured for safety monitoring. RDW was calculated with: standard deviation of the mean cell size divided by the mean corpuscular volume of the red cells multiplied by 100</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Red Blood Cell Distribution Width (RDW)</title>
          <description>Red blood cell distribution width (RDW) was measured for safety monitoring. RDW was calculated with: standard deviation of the mean cell size divided by the mean corpuscular volume of the red cells multiplied by 100</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>percentage of variation of red cells</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.14"/>
                    <measurement group_id="O2" value="-0.15" spread="0.22"/>
                    <measurement group_id="O3" value="0.18" spread="0.10"/>
                    <measurement group_id="O4" value="-0.44" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Platelet Count</title>
        <description>Platelet count was measured for safety monitoring.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Platelet Count</title>
          <description>Platelet count was measured for safety monitoring.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>K/uL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="4.61"/>
                    <measurement group_id="O2" value="6.54" spread="5.13"/>
                    <measurement group_id="O3" value="13.5" spread="4.9"/>
                    <measurement group_id="O4" value="28.7" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Aspartate Aminotransferase (AST)</title>
        <description>Aspartate aminotransferase was measured for safety monitoring.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Aspartate Aminotransferase (AST)</title>
          <description>Aspartate aminotransferase was measured for safety monitoring.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="0.67"/>
                    <measurement group_id="O2" value="-1.25" spread="0.81"/>
                    <measurement group_id="O3" value="2.33" spread="0.82"/>
                    <measurement group_id="O4" value="4.46" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Alanine Aminotransferase (ALT)</title>
        <description>Alanine aminotransferase was measured for safety monitoring.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Alanine Aminotransferase (ALT)</title>
          <description>Alanine aminotransferase was measured for safety monitoring.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="0.89"/>
                    <measurement group_id="O2" value="-3.46" spread="1.51"/>
                    <measurement group_id="O3" value="1.28" spread="1.37"/>
                    <measurement group_id="O4" value="5.46" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Total Bilirubin</title>
        <description>Total Bilirubin was measured for safety monitoring.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Total Bilirubin</title>
          <description>Total Bilirubin was measured for safety monitoring.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.03"/>
                    <measurement group_id="O2" value="-0.02" spread="0.03"/>
                    <measurement group_id="O3" value="-0.16" spread="0.05"/>
                    <measurement group_id="O4" value="-0.18" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Alkaline Phosphatase</title>
        <description>Serum alkaline phosphatase was measured for safety monitoring.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Alkaline Phosphatase</title>
          <description>Serum alkaline phosphatase was measured for safety monitoring.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.94" spread="1.45"/>
                    <measurement group_id="O2" value="-2.83" spread="1.55"/>
                    <measurement group_id="O3" value="-8.97" spread="1.44"/>
                    <measurement group_id="O4" value="-14.1" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Lipid Panel</title>
        <description>Plasma lipids were measured for safety monitoring.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Lipid Panel</title>
          <description>Plasma lipids were measured for safety monitoring.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.55" spread="2.53"/>
                    <measurement group_id="O2" value="-15.1" spread="5.8"/>
                    <measurement group_id="O3" value="-13.4" spread="4.5"/>
                    <measurement group_id="O4" value="-14.9" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.55" spread="1.18"/>
                    <measurement group_id="O2" value="-4.38" spread="1.21"/>
                    <measurement group_id="O3" value="-12.6" spread="1.3"/>
                    <measurement group_id="O4" value="-14.6" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.00" spread="2.10"/>
                    <measurement group_id="O2" value="-7.13" spread="5.44"/>
                    <measurement group_id="O3" value="0.57" spread="4.05"/>
                    <measurement group_id="O4" value="3.92" spread="6.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.36" spread="8.66"/>
                    <measurement group_id="O2" value="-23.5" spread="7.4"/>
                    <measurement group_id="O3" value="-7.40" spread="4.57"/>
                    <measurement group_id="O4" value="-31.7" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Glucose Levels</title>
        <description>Glucose will be measured in a fasting serum sample at Quest Lab.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Glucose Levels</title>
          <description>Glucose will be measured in a fasting serum sample at Quest Lab.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="1.74"/>
                    <measurement group_id="O2" value="0.04" spread="2.02"/>
                    <measurement group_id="O3" value="-2.78" spread="1.44"/>
                    <measurement group_id="O4" value="-8.54" spread="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin</title>
        <description>Insulin will be measured using an immunoassay at Quest lab.</description>
        <time_frame>12 weeks from baseline</time_frame>
        <population>All randomized and treated participants with data available at the given time-point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
          </group>
          <group group_id="O2">
            <title>LY2452473 Dose 1</title>
            <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O3">
            <title>LY2452473 Dose 2</title>
            <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
          <group group_id="O4">
            <title>LY2452473 Dose 3</title>
            <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin</title>
          <description>Insulin will be measured using an immunoassay at Quest lab.</description>
          <population>All randomized and treated participants with data available at the given time-point.</population>
          <units>uIU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.93"/>
                    <measurement group_id="O2" value="0.36" spread="1.52"/>
                    <measurement group_id="O3" value="-1.63" spread="0.68"/>
                    <measurement group_id="O4" value="-1.00" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo: The participants will receive pills containing no active drug daily for 12-weeks.</description>
        </group>
        <group group_id="E2">
          <title>LY2452473 Dose 1</title>
          <description>The participants will receive 1 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
        </group>
        <group group_id="E3">
          <title>LY2452473 Dose 2</title>
          <description>The participants will receive 5 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
        </group>
        <group group_id="E4">
          <title>LY2452473 Dose 3</title>
          <description>The participants will receive 15 mg LY2452473 daily for 12-weeks.&#xD;
LY2452473: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (24.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastatic ocular melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (24.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oesophageal food impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lyme Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Norovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="11" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hand injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Palate injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Biopsy skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood iron decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST segment depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle impingement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Thyroid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Taste disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Scrotal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin induration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shalender Bhasin, Principal Investigator</name_or_title>
      <organization>Brigham and Women's hospital</organization>
      <phone>617 525 9150</phone>
      <email>sbhasin@bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

